期刊文献+

慢性心力衰竭患者血清MMP-2、9水平及意义 被引量:6

The Levels and Significance of Serum Matrix Metalloproteinases-2,9 in Patients with Chronic Heart Failure
下载PDF
导出
摘要 目的:通过检测慢性心力衰竭患者(chronic heart failure,CHF)血清基质金属蛋白酶2、9(matrix metalloproteinases-2,9,MMP-2,9)水平,从而协助评价患者心功能状况。方法:2015年1月-2017年11月在笔者所在医院住院诊断为慢性心功能衰竭患者214例,并按照NYHA心功能分级分为Ⅰ~Ⅳ级,对照组选择同期健康体检者207例,同时行血清MMP-2、9及心脏彩超检查。结果:慢性心力衰竭患者的血清MMP-2、9较对照组明显升高(P<0.05),且不同NYHA心功能分级患者血清MMP-2、9水平差异有统计学意义(P<0.05)。结论:通过检测MMP-2、9可协助评价心功能衰竭严重程度。 Objective:To evaluate the cardiac function of patients by detecting the serum levels of matrix metalloproteinase 2 and 9.Method:214 cases diagnosed as heart failure in our hospital were included from January 2015 to November 2017.These patients were divided into Ⅰ-Ⅳ grades according to the NYHA cardiac function classification.207 healthy people were set as the control group.The serum matrix metalloproteinases-2,9 measure and cardiac color Doppler examination were performed in both two groups.Result:The serum matrix metalloproteinases-2,9 in the patients with chronic heart failure were significantly higher than those in the control group(P〈0.05),and there was significant difference in serum matrix metalloproteinases-2,9 levels among different NYHA cardiac function classification(P〈0.05).Conclusion:The detection of serum matrix metalloproteinases-2,9 can be used to evaluate the severity of heart failure.
作者 李镇 邵名亮 胡龙 冯启凡 LI Zhen;SHAO Mingliang;HU Long(The People's Hospital of Xuancheng City,Xuancheng 242000,China)
机构地区 宣城市人民医院
出处 《中外医学研究》 2018年第29期54-55,共2页 CHINESE AND FOREIGN MEDICAL RESEARCH
关键词 慢性心力衰竭 血清基质金属蛋白酶2、9 NYHA心功能分级 Chronic heart failure Serum matrix metalloproteinases-2, 9 Cardiac function classification of NYHA
  • 相关文献

参考文献6

二级参考文献32

  • 1吴薇,冯相平,陈新山.基质金属蛋白酶与心血管疾病及其法医学意义[J].中国法医学杂志,2005,20(1):37-40. 被引量:18
  • 2牛杏果,赵玉兰.慢性心力衰竭心肌重塑机制及干预治疗[J].心血管病学进展,2005,26(3):281-284. 被引量:20
  • 3汪靖,裘存新,吴捷华.充血性心力衰竭患者血清心肌肌钙蛋白测定的临床意义[J].心脑血管病防治,2006,6(5):284-286. 被引量:6
  • 4叶任高 主编.内科学:第5版[M].北京:人民卫生出版社,2001.824.
  • 5PEMBERTON C J,JOHNSON M L,YANDLETG,et al.Deconvolution analysis of cardiac natriuretic peptides during acute volume overload[J].Hypertension,2000,36 (3):355-359.
  • 6HAMMERER LERCHER A,NEUBAUER E,MULLER S,et al.Head to head comparison of N-terminal pro-brain natriuretic peptide,brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction[J].Clin Chim Acta,2001,310 (2):193-197.
  • 7YAMAZAKI T,LEE J D,SHIMIZU H,et al.Circulating matrix metalloproteinase-2 is elevated in patients with congestive heart failure[J].Eur J Heart Fail,2004,6 (1):41-45.
  • 8SPINALEFG,COKERML,HEUNGLJ,etal.A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure[J].Circulation,2000,102 (16):1944-1949.
  • 9Hartmann F,Packer M,Coats AJ,et al.Prognostic impact of plasma Nterminal pro-brain natriuretic peptide in severe chronic congestive heart failure:a substudy of the Carvedilol Prospective Randomized Cumulative Survival(COPERNICUS) trial[J].Circulation,2004; 110 (13):1780-6.
  • 10Spinale FG,Coker ML,Heung LJ,et al.A matrix metalloproteinase indunction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure[J].Cireulation,2000; 102 (16):1944-9.

共引文献1360

同被引文献92

引证文献6

二级引证文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部